Stockreport

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025)Treatment with UGN-102 resulted in durable complete respon [Read more]